| |OCTOBER 20249BFI & BIRAC INK A LETTER OF INTENT TO ADVANCE BIOMEDICAL INNOVATIONLUPIN FORAYS INTO NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDABlockchain for Impact (BFI), a philanthropic organisation, has signed a Letter of Intent to collaborate with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology, Government of India, marking a significant step forward in promoting biomedical innovation and biotechnology startups.The announcement of this strategic Letter of Intent was a significant step forward for both BFI and BIRAC in their efforts to stimulate biomedical research. BFI and BIRAC stated that it arrived at an appropriate time for India's economic growth. The Indian bioeconomy was valued at more than $100 billion in 2022 and is expected to reach $150 billion by 2025. Furthermore, India ranks 12th internationally in biotechnology and third in the Asia-Pacific region, with a 3-5% part of the global biotechnology market. The country is also ranked 40th in the Global Innovation Index 2022, demonstrating its expanding presence in the global science and technology sphere. Using this favorable growth environment and the positive policy support infrastructure, including the recently announced BioE3 policy, BFI intends to align its vision for biomedical research and innovation with that of the government, resulting in an impactful public-private collaboration to effectively leverage India's biomedical research capabilities. POLeading pharmaceutical company Lupin Limited has revealed a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to sell vonoprazan tablets in India. Lupin will be launching their new drug, Lupivon, in two different dosages of 10 mg and 20 mg.According to this agreement, Takeda has given Lupin non-exclusive rights to use vonoprazan patents for commercial purposes in India."We are very pleased to commercialize vonoprazan, a novel treatment option for acid peptic disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients," said, Rajeev Sibal, president India region formulations, Lupin. Acid peptic disorder (APD), such as gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), is commonly found in India. GERD is found in 5% to 28.5% of the population, while PUD affects approximately 8% of people. Old age, high BMI, non-vegetarian diet, tea/coffee consumption, smoking, and alcohol intake are all risk factors for GERD.Vonoprazan is a new type of medication known as a potassium-competitive acid blocker (P-CAB). In contrast to conventional acid reducers such as PPIs, vonoprazan provides distinctive qualities such as full proton pump inhibition after initial use, extended effectiveness for controlling nighttime acid breakthrough, and the ability to be taken regardless of meals. PO
< Page 8 | Page 10 >